Matthew C. Kapusta Sells 6,717 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 6,717 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now owns 580,795 shares of the company’s stock, valued at $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

uniQure Stock Performance

NASDAQ QURE opened at $13.15 on Friday. The company has a market capitalization of $640.73 million, a price-to-earnings ratio of -2.65 and a beta of 0.38. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The stock has a fifty day simple moving average of $15.05 and a 200 day simple moving average of $9.79. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Leerink Partners upped their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Mizuho upped their target price on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. HC Wainwright upped their target price on uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.89.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP acquired a new stake in uniQure in the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc acquired a new stake in uniQure in the third quarter valued at $53,000. Quarry LP acquired a new stake in uniQure in the third quarter valued at $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in uniQure in the third quarter valued at $69,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.